Recent Journal Articles – Archive
The Haase lab studies hypoxia responses in physiology and pathophysiology. This page provides links to recent original publications and review articles on HIF signaling in the kidney, HIF prolyl-hydroxylase domain oxygen sensors, kidney injury, erythropoietin regulation, renal anemia and iron metabolism, pulmonary hypertension and PHD inhibitors in clinical trials.
Clayton DB, AJP Renal. 2022
HIF-PHIs for the prevention of bladder injury.
Kobayashi et al., Kidney EPO production, Acta Physiologica. 2022
HIF-PHIs in CKD anemia: Regulation of EPO synthesis.
Guan et al., Kidney Int. 2022
Disruption of mitochondrial complex III in cap mesenchyme but not in ureteric progenitors results in defective nephrogenesis associated with amino acid deficiency.
Haase VH, iron ferric citrate, Kidney Int. 2022
Kidney Int. commentary on ferric citrate.
Burmakin et al., Acta Physiologica. 2021
HIF-PHIs in the regulation of renal hemodynamics.
Haase VH, Kidney Int Supplements. 2021
Hypoxia-inducible factor–prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease.
Ishii et al., Kidney Int. 2020
Kidney epithelial targeted mitochondrial transcription factor A deficiency results in progressive mitochondrial depletion associated with severe cystic disease.
Urrutia et al., Acta Physiologica. 2020
Inactivation of HIF-prolyl 4-hydroxylases 1, 2 and 3 in NG2-expressing cells induces HIF2-mediated neurovascular expansion independent of erythropoietin.
Haase VH, Kidney Int. 2020
Commentary on glycogen in acute kidney injury.
Sanghani & Haase, ACKD. 2019
Hypoxia-inducible factor activators in renal anemia: Current clinical experience.
Haase et al., Nephrol Dial Transplant. 2018
Effects of Vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis stimulating agents.
Haase VH, Am Journal of Kidney Dis. 2018
AJKD commentary on ARNT as a novel anti-fibrotic target in chronic kidney disease.
Haase VH, Exp Cell Res. 2017
Therapeutic targeting of the HIF oxygen-sensing pathway: Lessons learned from clinical studies.
Haase VH, Hemodial Int. 2017
HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism.
Kobayashi et al., Kidney Int. 2017
Hypoxia-inducible factor prolyl-4-hydroxylation in FOXD1 lineage cells is essential for normal kidney development.
Pergola et al., Kidney Int. 2016
Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease.
Kobayashi et al., JCI. 2016
Distinct subpopulations of FOXD1 stroma-derived cells regulate renal erythropoietin.
Farsijani et al., JCI. 2016
Renal epithelium regulates erythropoiesis via HIF-dependent suppression of erythropoietin.
Urrutia et al., Blood. 2016
Prolyl-4-hydroxylase 2 and 3 coregulate murine erythropoietin in brain pericytes.
Kapitsinou et al., MCB. 2016
The Endothelial Prolyl-4-Hydroxylase Domain 2/Hypoxia-Inducible Factor 2 Axis Regulates Pulmonary Artery Pressure in Mice.